XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisition of Pionyr Therapeutics (Tables)
9 Months Ended
Sep. 30, 2023
Business Combinations [Abstract]  
Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the Acquisition date (in thousands):

 

Assets Acquired

As of August 4, 2023

 

Cash and cash equivalents

$

40,926

 

Marketable securities

 

20,362

 

Prepaid expenses and other current assets

 

1,359

 

Right-of-use-asset

 

3,889

 

Deposits and other assets

 

406

 

Total assets acquired

$

66,942

 

Liabilities Assumed

 

 

Accounts payable

 

(2,844

)

Accrued expenses and other current liabilities

 

(8,097

)

Operating lease liability

 

(1,485

)

Long-term portion of operating lease liability

 

(5,647

)

Other long term liabilities

 

(852

)

Total liabilities assumed

$

(18,925

)

 

 

 

Net assets acquired (1)

$

48,017

 

(1) Net assets acquired does not include the remaining costs to complete the wind down of Pionyr development activities and operations.

Schedule of Fair Value of Equity Issued and Consideration Transferred

Fair value of equity issued and consideration transferred in connection with the Acquisition (in thousands):

 

 

As of August 4, 2023

 

Issuance of Series A Preferred Stock

$

32,837

 

Issuance of common stock

 

14,236

 

Cash consideration paid to settle Pionyr restricted stock units ("RSUs") and stock options

 

738

 

Cash consideration paid to Pionyr unaccredited stockholders

 

206

 

Total

$

48,017